Harvard Apparatus Regenerative Technology Inc. (HRGN)

OTCMKTS · Delayed Price · Currency is USD

1.720

-0.050 (-2.82%)

At close: Mar 4, 2026

-32.89% (1Y)

Market Cap	31.12M
Revenue (ttm)	743.00K
Net Income (ttm)	-6.53M
Shares Out	17.58M
EPS (ttm)	-0.40
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,425
Average Volume	5,998
Open	1.720
Previous Close	1.770
Day's Range	1.720 - 1.720
52-Week Range	0.936 - 2.550
Beta	-0.13
RSI	49.62
Earnings Date	Mar 30, 2026

About HRGN

Harvard Apparatus Regenerative Technology Inc., a clinical-stage biotechnology company, focuses on developing regenerative-medicine treatments for disorders of the gastro-intestinal system and other organs resulting from cancer, trauma, or birth defects. Its lead product candidate is Cellspan Esophageal Implant for the treatment of severe esophageal disease. The company’s pipeline includes organ-regeneration technology for the repair or replacement of diseased or damaged organs; and product candidates to treat conditions of the esophagus, inclu... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2009

Employees 8

Stock Exchange OTCMKTS

Ticker Symbol HRGN

Full Company Profile

Financial Performance

In 2024, HRGN's revenue was $430,000, an increase of 317.48% compared to the previous year's $103,000. Losses were -$7.73 million, -14.30% less than in 2023.

Financial Statements

News

There is no news available yet.